Matti Sällberg
Professor/Biomedical Analyst
E-mail: matti.sallberg@ki.se
Telephone: +46852483803
Visiting address: Nobels väg 7, 17165 Solna
Postal address: H5 Laboratoriemedicin, H5 Klin Mikrobiologi Sällberg, 141 52 Huddinge
Part of:
- Department of Laboratory Medicine
- Division of Clinical Microbiology at Labmed
- VIVAC research group: Vaccines and Immunotherapies against Viruses And Cancer – Matti Sällberg
About me
- Matti Sällberg, DDS, PhD, is a Professor of Biomedical Analysis. Went to School of Dentistry at Karolinska Institutet 1988-1992, PhD dissertation in December 1992. Post doctoral period at Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, Nov 1994-May 1996. Associate professor (Docent) at Karolinska Institutet in 1997. Professor in Biomedical Analysis from December 2000, and head of Department of Laboratory Medicine during the period 2011-2022.
Research
- The major research interest is understanding chronic viral hepatitis, cancer, and severe viral infections to develop new preventive and therapeutic strategies. A large part of the work is dedicated to gene and cell-based therapies, so called GTMPs and ATMPs.
Teaching
- I have since my time at the school of dentistry participated in undergraduate and graduate teaching in cell biology, virology and infectious disease. The main teaching efforts are in virology within many of the undergraduate programs at Karolinska Institutet.
Articles
- Article: GUT. 2025;74(7):1125-1136Maravelia P; Yao H; Cai C; Silva DN; Fransson J; Nilsson OB; Lu Y-CW; Micke P; Botling J; Gatto F; Rovesti G; Carlsten M; Sallberg M; Stal P; Jorns C; Buggert M; Pasetto A
- Article: GASTROENTEROLOGY. 2024;167(3):522-537Tran CS; Kersten J; Yan J; Breinig M; Huth T; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlen G; Frelin L; Kuehnel F; Vondran FWR; Breuhahn K; Meuleman P; Heikenwaelder M; Schirmacher P; Bartenschlager R; Laketa V; Roessler S; Tschaharganeh DF; Saellberg M; Lohmann V
- Article: MOLECULAR THERAPY. 2024;32(2):540-555Yan J; Bangalore CR; Nikouyan N; Appelberg S; Silva DN; Yao H; Pasetto A; Weber F; Weber S; Larsson O; Hoglund U; Bogdanovic G; Grabbe M; Aleman S; Szekely L; Szakos A; Tuvesson O; Gidlund E-K; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; Mirazimi A; Ahlen G; Sallberg M
- Article: CELL HOST & MICROBE. 2023;31(6):928-936.e4Adamo S; Gao Y; Sekine T; Mily A; Wu J; Storgard E; Westergren V; Filen F; Sandberg JK; Sallberg M; Bergman P; Llewellyn-Lacey S; Ljunggren H-G; Price DA; Ekstrom A-M; Sette A; Grifoni A; Buggert M
- Journal article: VACCINE INSIGHTS. 2023;02(05):167-173Sällberg M; Gidlund E-K
- Article: GUT. 2023;72(6):1186-1195Burm R; Maravelia P; Ahlen G; Ciesek S; Perez NC; Pasetto A; Urban S; Van Houtte F; Verhoye L; Wedemeyer H; Johansson M; Frelin L; Sallberg M; Meuleman P
- Article: MOLECULAR THERAPY. 2023;31(2):387-397Hawman DW; Meade-White K; Leventhal S; Appelberg S; Ahlen G; Nikouyan N; Clancy C; Smith B; Hanley P; Lovaglio J; Mirazimi A; Sallberg M; Feldmann H
- Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821Appelberg S; Ahlen G; Yan J; Nikouyan N; Weber S; Larsson O; Hoglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sallberg M
- Article: FRONTIERS IN IMMUNOLOGY. 2022;13:896242Silva DN; Chrobok M; Rovesti G; Healy K; Wagner AK; Maravelia P; Gatto F; Mazza M; Mazzotti L; Lohmann V; Chen MS; Sallberg M; Buggert M; Pasetto A
- Article: JOURNAL OF VIROLOGY. 2022;96(3):e0156821-e01521Appelberg S; John L; Pardi N; Vegvari A; Bereczky S; Ahlen G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sallberg M; Neogi U; Weissman D; Mirazimi A
- Article: NATURE MICROBIOLOGY. 2021;6(2):187-195Hawman DW; Ahlen G; Appelberg KS; Meade-White K; Hanley PW; Scott D; Monteil V; Devignot S; Okumura A; Weber F; Feldmann H; Sallberg M; Mirazimi A
- Article: JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):128-138Maravelia P; Frelin L; Ni Y; Perez NC; Ahlen G; Jagya N; Verch G; Verhoye L; Pater L; Johansson M; Pasetto A; Meuleman P; Urban S; Sallberg M
- Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306Sandberg JT; Varnaite R; Christ W; Chen P; Muvva JR; Maleki KT; Garcia M; Dzidic M; Folkesson E; Skagerberg M; Ahlen G; Frelin L; Sallberg M; Eriksson LI; Rooyackers O; Sonnerborg A; Buggert M; Bjorkstrom NK; Aleman S; Stralin K; Klingstrom J; Ljunggren H-G; Blom K; Gredmark-Russ S
- Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjarvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlen G; Asghar M; Sallberg M; Vesterbacka J; Nowak P; Vegvari A; Sonnerborg A; Treutiger CJ; Neogi U
- Article: GUT. 2020;69(12):2203-2213Lutckii A; Strunz B; Zhirkov A; Filipovich O; Rukoiatkina E; Gusev D; Lobzin Y; Fischler B; Aleman S; Sallberg M; Bjorkstrom NK
- Article: JOURNAL OF IMMUNOLOGY. 2020;205(9):2437-2446Varnaite R; Garcia M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlen G; Frelin L; Sallberg M; Blom K; Klingstrom J; Gredmark-Russ S
- Article: BMJ OPEN. 2020;10(9):e035996Busch K; Hansson F; Holton M; Lagging M; Westin J; Kovamees J; Sallberg M; Soderholm J
- Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2020;16(2):251-268Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
- Article: JOURNAL OF NEUROLOGY. 2019;266(9):2208-2215Soderholm J; Yilmaz A; Svenningsson A; Busch K; Wejstal R; Brolund A; Kovamees J; Sallberg M; Lagging M; Gisslen M
- Article: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2019;31(4):506-513Lybeck C; Brenndorfer ED; Sallberg M; Montgomery SM; Aleman S; Duberg A-S
- Article: GUT. 2018;67(8):1525-1535Levander S; Holmstrom F; Frelin L; Ahlen G; Rupp D; Long G; Bartenschlager R; Sallberg M
- Journal article: JOURNAL OF HEPATOLOGY. 2018;68:s307Söderholm J; Buesch K; Frelin L; Brolund A; Kövamees J; Sällberg M; Lagging M
- Journal article: JOURNAL OF HEPATOLOGY. 2018;68:s307-s308Söderholm J; Yilmaz A; Buesch K; Wejstál R; Brolund A; Kövamees J; Sällberg M; Lagging M; Gisslén M
- Article: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2018;66(1):106-111Einberg AP; Brenndorfer ED; Frelin L; Hallberg L; Sallberg M; Fischler B
- Article: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2017;65(6):608-612Einberg AP; Duberg A-S; Filipovich O; Nystrom J; Zhirkov A; Brenndorfer ED; Frelin L; Rukoiatkina E; Lobzin Y; Sallberg M; Fischler B; Lutckii A
- Article: JOURNAL OF VIROLOGY. 2017;91(9):e00010-e00017Balasiddaiah A; Davanian H; Aleman S; Pasetto A; Frelin L; Sallberg M; Lohmann V; Koh S; Bertoletti A; Chen M
- Article: ONCOTARGET. 2017;8(3):4530-4542Davanian H; Balasiddaiah A; Heymann R; Sundstrom M; Redenstrom P; Silfverberg M; Brodin D; Sallberg M; Lindskog S; Weiner CK; Chen M
- Article: VACCINE. 2016;34(25):2821-2833Levander S; Sallberg M; Ahlen G; Frelin L
- Article: SCIENTIFIC REPORTS. 2016;6:24991Functional differences in hepatitis C virus nonstructural (NS) 3/4A-and 5A-specific T cell responsesHolmstrom F; Chen M; Balasiddaiah A; Sallberg M; Ahlen G; Frelin L
- Article: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2016;3:16016Ahlen G; Frelin L; Holmstrom F; Smetham G; Augustyn S; Sallberg M
- Article: PLOS ONE. 2015;10(6):e0128466Bansal R; Frelin L; Brenndorfer ED; Storm G; Prakash J; Sallberg M
- Article: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2015;41(6):532-543Hedenstierna M; Weiland O; Brass A; Bankwitz D; Behrendt P; Uhnoo I; Aleman S; Cardell K; Fryden A; Norkrans G; Eilard A; Glaumann H; Pietschmann T; Sallberg M; Brenndorfer ED
- Article: MOLECULAR THERAPY. 2015;23(3):578-590Brass A; Frelin L; Milich DR; Saellberg M; Ahlen G
- Article: JOURNAL OF IMMUNOLOGY. 2014;192(4):1671-1680Brenndoerfer ED; Brass A; Karthe J; Ahlen G; Bode JG; Saellberg M
- Article: JOURNAL OF INFECTIOUS DISEASES. 2013;208(6):1008-1019Fournillier A; Frelin L; Jacquier E; Ahlen G; Brass A; Gerossier E; Holmstrom F; Broderick KE; Sardesai NY; Bonnefoy J-Y; Inchauspe G; Sallberg M
- Article: MOLECULAR THERAPY. 2013;21(9):1796-1805Weiland O; Ahlen G; Diepolder H; Jung M-C; Levander S; Fons M; Mathiesen I; Sardesai NY; Vahlne A; Frelin L; Sallberg M
- Article: MOLECULAR THERAPY NUCLEIC ACIDS. 2013;2(8):e114Koh S; Shimasaki N; Suwanarusk R; Ho ZZ; Chia A; Banu N; Howland SW; Ong ASM; Gehring AJ; Stauss H; Renia L; Sallberg M; Campana D; Bertoletti A
- Article: ALLERGY. 2013;68(4):549-552Hamsten C; Starkhammar M; Tran TAT; Johansson M; Bengtsson U; Ahlen G; Sallberg M; Gronlund H; van Hage M
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2013;433(1):31-35Rahbin N; Frelin L; Aleman S; Hultcrantz R; Sallberg M; Brenndorfer ED
- Article: METHODS IN MOLECULAR BIOLOGY. 2013;940:239-267Ahlén G; Sällberg M; Frelin L
- Article: JOURNAL OF IMMUNOLOGY. 2012;189(9):4510-4519Pasetto A; Frelin L; Aleman S; Holmstrom F; Brass A; Ahlen G; Brenndorfer ED; Lohmann V; Bartenschlager R; Sallberg M; Bertoletti A; Chen M
- Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2012;28(9):1052-1058Perdomo MF; Sallberg M; Vahlne A
- Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 8):1680-1686Ahlen G; Chen A; Roe B; Falkeborn T; Frelin L; Hall WW; Sallberg M; Soderholm J
- Article: GUT. 2012;61(4):589-596Brenndorfer ED; Brass A; Soderholm J; Frelin L; Aleman S; Bode JG; Sallberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 2):247-258Pasetto A; Frelin L; Brass A; Yasmeen A; Koh S; Lohmann V; Bartenschlager R; Magalhaes I; Maeurer M; Sallberg M; Chen M
- Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(1):55-59Malik IR; Chen A; Brass A; Ahlen G; Rahman M; Sallberg M; Qureshi JA; Frelin L
- Article: APMIS. 2011;119(7):412-420Soderberg C; Marmur J; Eckes K; Glaumann H; Sallberg M; Frelin L; Rosenberg P; Stal P; Hultcrantz R
- Article: JOURNAL OF IMMUNOLOGY. 2011;186(9):5107-5118Chen A; Ahlen G; Brenndorfer ED; Brass A; Holmstrom F; Chen M; Soderholm J; Milich DR; Frelin L; Sallberg M
- Journal article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2011;56(Supplement 2):74Perdomo M; Sällberg M; Vahlne A
- Article: DRUG NEWS AND PERSPECTIVES. 2010;23(10):647-653Frelin L; Brass A; Ahlen G; Brenndorfer ED; Chen M; Sallberg M
- Article: HEPATOLOGY. 2010;52(5):1553-1563Brenndorfer ED; Weiland M; Frelin L; Derk E; Ahlen G; Jiao J; Bode JG; Sallberg M
- Article: SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH. 2010;41(6):1359-1367Witthajitsomboon N; Chen A; Lorroengsil S; Sallberg M; Pantuwatana S
- Article: JOURNAL OF INFECTIOUS DISEASES. 2010;201(12):1867-1879Nystrom J; Chen A; Frelin L; Ahlen G; Koh S; Brass A; Peterson DL; Fons M; Milich DR; Hultgren C; Sallberg M
- Article: GENE THERAPY. 2010;17(6):811-814Gill HS; Soderholm J; Prausnitz MR; Sallberg M
- Journal article: JOURNAL OF HEPATOLOGY. 2010;52:s265Brenndörfer ED; Frelin L; Söderholm J; Bode JG; Sällberg M
- Journal article: JOURNAL OF HEPATOLOGY. 2010;52:s265Brenndörfer ED; Weiland M; Frelin L; Derk E; Ahlen G; Bode JG; Sällberg M
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2009;284(41):28343-28351Kriegs M; Buerckstuemmer T; Himmelsbach K; Bruns M; Frelin L; Ahlen G; Sallberg M; Hildt E
- Article: HEPATOLOGY. 2009;49(6):1810-1820Brenndorfer ED; Karthe J; Freblin L; Cebula P; Erhardt A; Esch JSA; Hengel H; Bartenschlager R; Sallberg M; Haussinger D; Bode JG
- Article: JOURNAL OF IMMUNOLOGY. 2009;182(11):6670-6681Lee BO; Tucker A; Frelin L; Sallberg M; Jones J; Peters C; Hughes J; Whitacre D; Darsow B; Peterson DL; Milich DR
- Article: GUT. 2009;58(4):560-569Ahlen G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grander D; Frelin L; Sallberg M
- Journal article: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2009;47(01)Brenndörfer E; Karthe J; Cebula P; Erhardt A; Frelin L; Schulte am Esch J; Häussinger D; Bode J; Sällberg M
- Article: VACCINE. 2008;26(47):5967-5972Nystrom J; Cardell K; Bjornsdottir TB; Fryden A; Hultgren C; Sallberg M
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(34):12515-12520Perdomo MF; Levi M; Sallberg M; Vahlne A
- Article: JOURNAL OF INFECTIOUS DISEASES. 2008;198(3):299-304Cardell K; Akerlind B; Sallberg M; Fryden A
- Journal article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;96(3):403-409ZHANG ZX; CHEN M; WALLHAGEN K; TROJNAR J; MAGNIUS LO; WAHREN B; SALLBERG M
- Journal article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;90(2):199-203LINDE A; SODERSTROM R; SMITH CIE; SALLBERG M; DAHL H; GRUBB R; BJORKANDER J; HAMMARSTROM L
- Journal article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;98(3):382-387ZHANG ZX; SONNERBORG A; SALLBERG M
- Journal article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;84(1):116-121Sällberg M; Norder H; Lindh G; Magnius LO
- Article: JOURNAL OF MOLECULAR BIOLOGY. 2008;379(5):1119-1129Watts NR; Cardone G; Vethanayagam JG; Cheng N; Hultgren C; Stahl SJ; Steven AC; Sallberg M; Wingfield PT
- Journal article: SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH. 2008;39(3):387-393Lorroengsil S; Chen A; Sällberg M; Pantuwatana S
- Journal article: DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES. 2007;4(4):253-266Sällberg M; Weiland M; Frelin L
- Article: JOURNAL OF IMMUNOLOGY. 2007;179(7):4741-4753Ahlen G; Soderholm J; Tjelle T; Kjeken R; Frelin L; Hoglund U; Blomberg P; Fons M; Mathiesen I; Sallberg M
- Article: JOURNAL OF MEDICAL VIROLOGY. 2007;79(6):701-713Desombere I; Van Vlierberghe H; Weiland O; Hultgren C; Sallberg M; Quiroga J; Carreno V; Leroux-Roels G
- Article: VACCINE. 2007;25(9):1593-1606Billaud J-N; Peterson D; Lee BO; Maruyama T; Chen A; Sallberg M; Garduno F; Goldstein P; Hughes J; Jones J; Milich D
- Article: JOURNAL OF INFECTIOUS DISEASES. 2006;194(12):1724-1728Soderholm J; Sallberg M
- Article: GUT. 2006;55(10):1475-1483Frelin L; Brenndorfer ED; Ahlen G; Weiland M; Hultgren C; Alheim M; Glaumann H; Rozell B; Milich DR; Bode JG; Sallberg M
- Article: GUT. 2006;55(2):266-274Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
- Journal article: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2006;44(01)Brenndörfer E; Frelin L; Alheim M; Hultgren C; Ahlen G; Häussinger D; Sällberg M; Bode J
- Article: JOURNAL OF INFECTIOUS DISEASES. 2005;192(12):2112-2116Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sällberg M
- Article: JOURNAL OF MEDICAL VIROLOGY. 2005;77(4):481-485Björnsdottir TB; Stanzeit B; Sällberg M; Löve A; Hultgren C
- Article: JOURNAL OF VIROLOGY. 2005;79(21):13656-13666Billaud JN; Peterson D; Barr M; Chen A; Sallberg M; Garduno F; Goldstein P; McDowell W; Hughes J; Jones J; Milich D
- Article: JOURNAL OF VIROLOGY. 2005;79(21):13641-13655Billaud JN; Peterson D; Schödel F; Chen A; Sallberg M; Garduno F; Goldstein P; McDowell W; Hughes J; Jones J; Milich D
- Article: JOURNAL OF VIROLOGY. 2005;79(5):3016-3027Chen M; Sällberg M; Hughes J; Jones J; Guidotti LG; Chisari FV; Billaud JN; Milich DR
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2004;101(41):14913-14918Chen MT; Billaud JN; Sällberg M; Guidotti LG; Chisari FV; Jones J; Hughes J; Milich DR
- Article: JOURNAL OF HEPATOLOGY. 2004;40(6):971-978Hultgren C; Desombere I; Leroux-Roels G; Quiroga JA; Carren V; Nilsson B; Weiland O; Sällberg M
- Article: GENE THERAPY. 2004;11(6):522-533Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
- Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;106(1):35-39Brostrom C; Sonnerborg A; Kim S; Sallberg M
- Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;105(1):59-64Gabrielli A; Zhang ZX; Cherubini G; Candela M; Savoldi S; Manzin A; Clementi M; Amoroso A; Sallberg M
- Article: JOURNAL OF VIROLOGY. 2003;77(12):6743-6752Karlsson AC; Deeks SG; Barbour JD; Heiken BD; Younger SR; Hoh R; Lane M; Sällberg M; Ortiz GM; Demarest JF; Liegler T; Grant RM; Martin JN; Nixon DF
- Article: GENE THERAPY. 2003;10(8):686-699Frelin L; Alheim M; Chen A; Söderholm J; Rozell B; Barnfield C; Liljeström P; Sällberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 2003;84(Pt 1):139-146Lazdina U; Alheim M; Nyström J; Hultgren C; Borisova G; Sominskaya I; Pumpens P; Peterson DL; Milich DR; Sällberg M
- Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2003;108(1):61-74Almroth G; Uhlin F; Ekermo B; Isaksson B; Kaijser B; Andersson B; Hahn-Zoric M; Sällberg M
- Article: PROTEIN AND PEPTIDE LETTERS. 2002;9(6):533-543Wade D; Flock JI; Edlund C; Löfving-Arvholm I; Sallberg M; Bergman T; Silveira A; Unson C; Rollins-Smith L; Silberring J; Richardson M; Kuusela P; Lankinen H
- Article: JOURNAL OF GENERAL VIROLOGY. 2002;83(Pt 12):3023-3033Cao TH; Desombere I; Vanlandschoot P; Sällberg M; Leroux-Roels G
- Article: JOURNAL OF HEPATOLOGY. 2002;36(3):408-416Rico MA; Quiroga JA; Subirá D; Garcia E; Castañón S; Sällberg M; Leroux-Roels G; Weiland O; Pardo M; Carreño V
- Journal article: DEN NORSKE TANNLEGEFORENINGS TIDENDE. 2002;112(2):122-127Sällberg M; Lundholm P
- Article: INTERVIROLOGY. 2002;45(4-6):350-361Sällberg M; Hughes J; Jones J; Phillips TR; Milich DR
- Article: VACCINE. 2001;20(5-6):771-788Milich DR; Hughes J; Jones J; Sällberg M; Phillips TR
- Article: JOURNAL OF VIROLOGY. 2001;75(23):11449-11456Cao TH; Meuleman P; Desombere I; Sällberg M; Leroux-Roels G
- Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2001;258(1-2):157-167Alheim M; Lazdina U; Milich DR; Sällberg M
- Article: JOURNAL OF VIROLOGY. 2001;75(14):6367-6374Lazdina U; Cao TH; Steinbergs J; Alheim M; Pumpens P; Peterson DL; Milich DR; Leroux-Roels G; Sällberg M
- Article: JOURNAL OF VIROLOGY. 2001;75(14):6359-6366Cao TH; Lazdina U; Desombere I; Vanlandschoot P; Milich DR; Sällberg M; Leroux-Roels G
- Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 6):1299-1308Lazdina U; Hultgren C; Frelin L; Chen M; Lodin K; Weiland O; Leroux-Roels G; Quiroga JA; Peterson DL; Milich DR; Sällberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 1):129-138Nicacio CD; Sällberg M; Hultgren C; Lundkvist Å
- Article: JOURNAL OF MEDICAL VIROLOGY. 2000;62(3):334-344Lazdina U; Hultgren C; Chen M; Fischler B; Weiland O; Mushahwar IK; Sällberg M
- Article: JOURNAL OF VIROLOGY. 2000;74(16):7587-7599Chen M; Sällberg M; Thung SN; Hughes J; Jones J; Milich DR
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 2000;7(3):377-383Iroegbu J; Birk M; Lazdina U; Sönnerborg A; Sällberg M
- Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2000;32(4):445-446Löve A; Chen M; Sällberg M
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 2000;7(1):58-63Zhang ZX; Lazdina U; Chen M; Peterson DL; Sällberg M
- Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1999;37(12):4153-4155Chen M; Fischler B; Hultgren C; Halasz R; Nemeth A; Sällberg M
- Article: CLINICAL INFECTIOUS DISEASES. 1999;29(6):1575-1577Hultgren C; Weiland O; Milich DR; Sällberg M
- Article: JOURNAL OF VIROLOGY. 1999;73(7):6191-6196Karlsson AC; Gaines H; Sällberg M; Lindbäck S; Sönnerborg A
- Article: CLINICAL INFECTIOUS DISEASES. 1999;28(3):537-540Halasz R; Fischler B; Nemeth A; Lundholm S; Sällberg M
- Article: PROTEIN AND PEPTIDE LETTERS. 1999;6(1):49-53Smoluch MT; Suder P; Kotlinska J; Sällberg M; Silberring J
- Article: GUT. 1999;44(2):274-278Halasz R; Barkholt L; Lara C; Hultgren C; Ando Y; Broomé U; Fischler B; Nemeth A; Ericzon BG; Sönnerborg A; Sällberg M
- Article: GASTROENTEROLOGY. 1999;116(1):135-143Chen M; Sällberg M; Sönnerborg A; Weiland O; Mattsson L; Jin L; Birkett A; Peterson D; Milich DR
- Article: ACTA BIOCHIMICA POLONICA. 1999;46(2):475-481Smoluch MT; Sällberg M; Silberring J
- Article: PEPTIDES. 1999;20(2):239-247Suder P; Kotlinska J; Smoluch MT; Sällberg M; Silberring J
- Article: AIDS. 1998;12(15):1973-1981Birk M; Flock JI; Sönnerborg A; Sallberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 1998;79:2381-2391Hultgren C; Milich DR; Weiland O; Sällberg M
- Article: JOURNAL OF HEPATOLOGY. 1998;29(1):36-44Amoroso A; Berrino M; Canale L; Cornaglia M; Guarrera S; Mazzola G; Savoldi S; Scolari F; Sällberg M; Clementi M; Gabrielli A
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 1998;5(4):463-466Visco-Comandini U; Hultgren C; Brostrom C; Birk M; Kim S; Sallberg M
- Article: HEPATOLOGY. 1998;28(1):219-224Chen M; Sällberg M; Sönnerborg A; Jin L; Birkett A; Peterson D; Weiland O; Milich DR
- Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1998;14(3):241-248Birk M; Vahlne A; Sönnerborg A; Sällberg M
- Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1998;36(1):255-257Lara C; Halasz R; Sönnerborg A; Sällberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 1997;78:2735-2746Zhang ZX; Chen M; Hultgren C; Birkett A; Milich DR; Sallberg M
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 1997;4(5):630-632Hultgren C; Milich DR; Sallberg M
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 1997;4(5):627-629Kebede T; Britton S; Fehniger T; Vahlne A; Sallberg M
- Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(9):2419-2421Sherefa K; Sallberg M; Johansson B; Salminen M; Sonnerborg A
- Article: JOURNAL OF INFECTIOUS DISEASES. 1997;176(1):281-285Fischler B; Lara C; Chen M; Sonnerborg A; Nemeth A; Sallberg M
- Article: JOURNAL OF VIROLOGY. 1997;71(7):5295-5303Sallberg M; Townsend K; Chen M; ODea J; Banks T; Jolly DJ; Chang SM; Lee WT; Milich DR
- Article: JOURNAL OF INFECTIOUS DISEASES. 1997;175(6):1294-1301Zhang ZX; Milich DR; Peterson DL; Birkett A; Schvarcz R; Weiland O; Sallberg M
- Journal article: JOURNAL OF VIROLOGY. 1997;71(5):3365-3374Townsend K; Sällberg M; O'Dea J; Banks T; Driver D; Sauter S; Chang SM; Jolly DJ; Mento SJ; Milich DR; Lee WT
- Journal article: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 1997;24(4):488Fischler B; Lara C; Chen M; Sönnerborg A; Nemeth A; Sällberg M
- Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(4):973-975Chen M; Sonnerborg A; Johansson B; Sallberg M
- Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1997;13(4):343-345Sonnerborg A; Durdevic S; Giesecke J; Sallberg M
- Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(3):783-784Lara C; Sallberg M; Johansson B; deRivera IL; Sonnerborg A
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 1997;4(1):104-106Ando Y; Sonnerborg A; Barkholt L; Birkett A; Ericzon BG; Sallberg M
- Article: JOURNAL OF GENERAL VIROLOGY. 1996;77:2721-2728Sallberg M; Zhang ZX; Chen M; Jin L; Birkett A; Peterson DL; Milich DR
- Article: HUMAN ANTIBODIES AND HYBRIDOMAS. 1996;7(3):106-112Steinbergs J; Kilchewska K; Lazdina U; Dishlers A; Ose V; Sällberg M; Tsimanis A
- Article: IMMUNOLOGY LETTERS. 1996;52(1):37-44Isaguliants MG; Nordlund S; Sallberg M; Smirnov VD; Ruden U; Wahren B
- Article: IMMUNOLOGY LETTERS. 1995;46(1-2):25-30SALLBERG M; BLIXT M; ZHANG ZX; EKSTRAND J
- Article: JOURNAL OF MEDICAL VIROLOGY. 1995;45(2):223-226CHEN M; YUN ZB; SALLBERG M; SCHVARCZ R; BERGQUIST I; BERGLUND HB; SONNERBORG A
- Article: JOURNAL OF MEDICAL VIROLOGY. 1995;45(1):50-55ZHANG ZX; YUN ZB; CHEN M; SONNERBORG A; SALLBERG M
- Journal article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1994;10(11):1551-1556SHEREFA K; SALLBERG M; SONNERBORG A
- Journal article: CLINICAL AND VACCINE IMMUNOLOGY. 1994;1(3):290-294ZHANG ZX; CHEN M; SONNERBORG A; SALLBERG M
- Journal article: CLINICAL AND VACCINE IMMUNOLOGY. 1994;1(3):336-341Samuelson A; Forsgren M; Johansson B; Wahren B; Sällberg M
- Journal article: JOURNAL OF MEDICAL VIROLOGY. 1994;43(1):62-68Sällberg M; Pumpen P; Zhang ZX; Lundholm P; Gusars I; Rudén U; Wahren B; Magnius LO
- Journal article: JOURNAL OF MEDICAL VIROLOGY. 1994;42(1):7-15Sällberg M; Rudén U; Wahren B; Magnius LO
- Journal article: JOURNAL OF CLINICAL PERIODONTOLOGY. 1993;20(10):746-751ENGSTROM PE; LARSSON A; NORHAGEN G; SMITH CIE; SALLBERG M; HELGELAND K; HAMMARSTROM L
- Journal article: JOURNAL OF GENERAL VIROLOGY. 1993;74 ( Pt 7):1335-1340Sällberg M; Pushko P; Berzinsh I; Bichko V; Sillekens P; Noah M; Pumpens P; Grens E; Wahren B; Magnius LO
- Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1993;90(10):4374-4378LEVI M; SALLBERG M; RUDEN U; HERLYN D; MARUYAMA H; WIGZELL H; MARKS J; WAHREN B
- Journal article: JOURNAL OF CLINICAL MICROBIOLOGY. 1992;30(8):1989-1994SALLBERG M; RUDEN U; WAHREN B; MAGNIUS LO
- Journal article: IMMUNOLOGY LETTERS. 1992;33(1):27-33SALLBERG M; RUDEN U; WAHREN B; MAGNIUS LO
- Journal article: IMMUNOLOGY LETTERS. 1991;30(1):59-68SALLBERG M; RUDEN U; MAGNIUS LO; NORRBY E; WAHREN B
- Journal article: MOLECULAR IMMUNOLOGY. 1991;28(7):719-726Sällberg M; Rudén U; Wahren B; Noah M; Magnius LO
- Journal article: JOURNAL OF MEDICAL VIROLOGY. 1991;33(4):248-252Sällberg M; Rudén U; Magnius LO; Harthus HP; Noah M; Wahren B
- Journal article: JOURNAL OF MEDICAL VIROLOGY. 1990;30(1):1-6Sällberg M; Norder H; Magnius LO
- Journal article: JOURNAL OF MEDICAL VIROLOGY. 1989;29(4):296-302Sälberg M; Norder H; Weiland O; Magnius L
- Journal article: JOURNAL OF CLINICAL MICROBIOLOGY. 1989;27(5):849-853Sällberg M; Magnius LO
- Show more
All other publications
- Preprint: BIORXIV. 2023Tran CS; Kersten J; Breinig M; Yan J; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlén G; Frelin L; Kühnel F; Breuhahn K; Vondran FWR; Meuleman P; Heikenwälder M; Schirmacher P; Sällberg M; Bartenschlager R; Laketa V; Tschaharganeh DF; Lohmann V
- Meeting abstract: JOURNAL OF IMMUNOLOGY. 2023;210(1):59.47Adamo S; Gao Y; Cai C; Muller TR; Niessl J; Akhirunnesa M; Ljunggren H-G; Sallberg M; Bergman P; Ekstrom A-M; Grifoni A; Sette A; Price DA; Buggert M
- Review: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100099Silva DN; Chrobok M; Ahlén G; Blomberg P; Sällberg M; Pasetto A
- Preprint: BIORXIV. 2021Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva J; Maleki K; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; The Karolinska COVID-19 Study Group; Eriksson L; Rooyackers O; Sönnerborg A; Buggert M; Björkström N; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S
- Preprint: BIORXIV. 2021Krishnan S; Nordqvist H; Ambikan A; Gupta S; Sperk M; Svensson-Akusjärvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlén G; Asghar M; Sällberg M; Vesterbacka J; Nowak P; Végvári Á; Sönnerborg A; Treutiger CJ; Neogi U
- Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1426Maravelia P; Potti AP; Sekine T; Silva DSN; Healy K; Chrobok M; Jorns C; Sallberg M; Buggert M; Pasetto A
- Letter: JOURNAL OF VIROLOGY. 2020;94(18):e01279-e01220Ahlen G; Frelin L; Nikouyan N; Weber F; Hoglund U; Larsson O; Westman M; Tuvesson O; Gidlund E-K; Cadossi M; Appelberg S; Mirazimi A; Sallberg M
- Preprint: BIORXIV. 2020Varnaitė R; García M; Glans H; Maleki K; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
- Review: FRONTIERS IN IMMUNOLOGY. 2020;11:552Sallberg M; Pasetto A
- Editorial comment: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2019;50(8):963-964Pasetto A; Ahlen G; Sallberg M
- Conference publication: JOURNAL OF HEPATOLOGY. 2017;66(1):S410-S411Buesch K; Hansson F; Holton M; Lagging M; Westin J; Kovamees J; Sallberg M; Soderholm J
- Review: EXPERT REVIEW OF VACCINES. 2016;15(5):629-640Chen M; Jagya N; Bansal R; Frelin L; Sallberg M
- Review: MEDICAL MICROBIOLOGY AND IMMUNOLOGY. 2015;204(1):131-135Sallberg M; Frelin L; Ahlen G; Sallberg-Chen M
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2014;60(1):S325Brenndoerfer ED; Hedenstierna M; Bankwitz D; Behrendt P; Brass A; Uhnoo I; Aleman S; Fryden A; Norkrans G; Eilard A; Glaumann H; Cardell K; Pietschmann T; Weiland O; Sallberg M
- Conference publication: JOURNAL OF HEPATOLOGY. 2014;60(1):S133EVALUATION OF A HEPATITIS C VIRUS THERAPEUTIC VACCINE CANDIDATE IN WILDTYPE- AND HCV-TRANSGENIC MICEHolmstrom F; Sallberg M; Ahlen G; Frelin L
- Conference publication: JOURNAL OF HEPATOLOGY. 2014;60(1):S127Brass A; Frelin L; Sallberg M; Ahlen G
- Review: DRUG RESISTANCE UPDATES. 2013;16(3-5):60-67Ahlen G; Frelin L; Brenndorfer ED; Brass A; Weiland O; Chen M; Sallberg M
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2013;58:S134Brenndorfer ED; Brass A; Karthe J; Ahlen G; Bode JG; Sallberg M
- Review: ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS. 2012;60(5):315-329Brenndorfer ED; Sallberg M
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2012;56:S302Brenndorfer ED; Brass A; Soderholm J; Frelin L; Bode JG; Sallberg M
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2011;54:S476-S477Frelin L; Ahlen G; Chen A; Brenndorfer ED; Brass A; Holmstrom F; Chen M; Soderholm J; Milich DR; Sallberg M
- Conference publication: JOURNAL OF HEPATOLOGY. 2011;54:S306-S307Ahlen G; Frelin L; Sallberg M
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2010;52:S239Chen A; Nystrom J; Frelin L; Ahlen G; Koh S; Peterson DL; Fons M; Milich D; Hultgren C; Sallberg M
- Review: HEPATOLOGY RESEARCH. 2010;40(2):115-124Jiao J; Wang J; Sallberg M
- Review: EXPERT OPINION ON BIOLOGICAL THERAPY. 2009;9(7):805-815DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving targetSallberg M; Frelin L; Weiland O
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S124Brenndoerfer E; Karthe J; Frelin L; Cebula P; Erhardt A; Hengel H; Bartenschlager R; Sallberg M; Haeussinger D; Bode J
- Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S47Frelin L; Brenndorfer ED; Ahlen G; Chen A; Tjelle T; Kjeken R; Fons M; Mathiesen I; Sallberg M
- Editorial comment: GENOME MEDICINE. 2009;1(1):15Frelin L; Sallberg M
- Meeting abstract: JOURNAL OF CLINICAL VIROLOGY. 2006;36:S112Soderholm J; Sallberg M
- Published conference paper: ANTIVIRAL RESEARCH. 2001;52(2):99-111Chen M; Sällberg M; Thung SN; Hughes J; Jones J; Milich DR
- Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2001;33(8):572-580Halasz R; Weiland O; Sällberg M
- Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2000;182(6):1756-1760Halasz R; Sällberg M; Lundholm S; Andersson G; Lager B; Glaumann H; Weiland O
- Published conference paper: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1998;248(3):690-695Wade D; Palma M; Löfving-Arvholm I; Sällberg M; Silberring J; F'lock JI
- Letter: JOURNAL OF INFECTIOUS DISEASES. 1998;177(1):264-265Sällberg M; Hultgren C
- Addendum: IMMUNOLOGY LETTERS. 1997;55(1):61Isaguliants MG; Nordlund S; Sallberg M; Smirnov VD; Ruden U; Wahren B
- Published conference paper: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 1995;13 Suppl 13:S95-S99Gabrielli A; Sambo P; Zhang ZX; Candela M; Savoldi S; Manzin A; Clementi M; Amoroso A; Sallberg M; Danieli G
- Other: CLINICAL AND VACCINE IMMUNOLOGY. 1995;2(3):385-386SAMUELSON A; FORSGREN M; SALLBERG M
- Other: JOURNAL OF INFECTIOUS DISEASES. 1995;171(5):1356-1359ZHANG ZX; CHEN M; SONNERBORG A; WEILAND O; SALLBERG M
- Other: JOURNAL OF CLINICAL MICROBIOLOGY. 1995;33(3):778-780CHEN M; SONNERBORG A; SALLBERG M
- Letter: JOURNAL OF INFECTIOUS DISEASES. 1995;171(2):509-511BROSTROM C; SONNERBORG A; SALLBERG M
- Book chapter: PEPTIDES. 1994;p. 715-718Sällberg M; Levi M; Rudén U; Pushko P; Bichko V; Magnius LO; Tsimanis A; Wahren B
- Book chapter: PEPTIDES. 1992;p. 723-724Sällberg M; Rudén U; Wahren B; Noah M; Magnius LO
- Show more
Grants
- Swedish Cancer Society1 January 2024We have studied viral hepatitis as a cause of cancer for almost 25 years. We have previously developed a therapeutic vaccine against hepatitis C virus which we tested in a phase I study on humans. We have used this knowledge and experience to develop a vaccine against COVID-19 in less than 3 years, which is now being tested in a phase I study on humans. We are now using all this experience and knowledge in our development of vaccines and immunotherapies against, above all, HBV and HDV. You cannot get rid of these viruses through today's treatment, and vaccines or immunotherapy are probably the best long-term ways to get the body to control these infections and reduce the risk of cancer. Chronic infections with HBV, HDV, and previously also HCV are leading causes of liver cancer globally. Today, HCV can be cured in >90% of all patients with a three-month treatment, but some develop liver cancer despite having cured the infection. Here we need to increase knowledge of how HCV establishes chronic infection and causes cancer. For HBV and HDV, new treatments are needed that lead to a so-called functional cure, i.e. you do not get rid of the infection but the body's immune system controls the infection, whereby the risk of cancer is greatly reduced. In addition, no further treatment is required. Thus, one strategy is to activate the body's immune response. During this period, we hope to be able to develop our treatments against HBV and HDV all the way to a clinical study in humans to see that the treatment activates the immune system as well in humans as in the animal models we have evaluated. our therapeutic vaccine can prevent co-infection with HBV and HDV, and also prevent mice with chronic HBV infection from being infected with HDV as well. The last is a big problem in countries in Asia. HDV shortens the time to serious liver disease by 75% compared to having only HBV. Thus, we see that our vaccines can be used to treat HBV and HDV, and also to prevent HDV infection.
- Swedish Research Council1 December 2022 - 30 November 2027The proposed doctoral program in advanced therapies (DPAT) focuses on preclinical development and clinical adoption of advanced therapy medicinal products (ATMP), a new class of drugs based on cells, genes or engineered tissues with great potential to effectively treat, or cure, a wide range of diseases. Today, patient access to ATMPs is limited by a lack of personnel with the knowledge of the field needed for these drugs to become routine clinical practice. A coordinated effort to ensure education of health care professionals is needed.DPAT targets teachers within programs relevant to the topicmedicine and dentistry, nursing, pharmacy and biomedical analyst education. The curriculum builds on the core doctoral training programs, complemented by newly co-developed courses and education activities about the ATMP development chain from research, via translation to implementation in health care, including manufacturing, quality control, regulatory and legal aspects, health economics, ethics, and entrepreneurship.DPAT is a national initiative by five Swedish universities, coordinated by Lund University. The universities contribute with their areas of strength and excellent research milieus within ATMP, as well as collaboration with internationally leading institutions in Europe and the US.By educating the teachers and connecting them closer to research, the doctoral program will significantly strengthen Sweden’s competence in this important field of tomorrows Health Care.
- Swedish Cancer Society1 January 2021Hepatitis B, C and D viruses are leading causes of serious liver damage and cancer. We intend to develop new immunotherapies and vaccines against these to minimize cancer risk and improve treatment results. We work a lot with so-called genetic vaccines, i.e. the vaccine consists of part of the genetic material for viruses. When the genetic vaccine is taken up in our cells, they will produce the vaccine protein that activates the immune system. The advantage of this type of vaccine is that it activates a broad immune system. We will now work on developing good genetic vaccines against Hepatitis B, C and D viruses to reduce the cancer risk. During the next three-year period, we hope to be able to start human studies with at least one of our vaccines. In a first study, we will test how the vaccine works in healthy volunteers. This will tell whether the vaccine is safe, what dose works best and whether it can activate the immune system that we think will be able to work against the infection. Our first goal is to test the therapeutic vaccine against hepatitis B. If it is safe and works well, we will also test it for the treatment of hepatitis D. We hope that our research will lead to better treatment of chronic hepatitis B, C and D virus infections. We do this by developing better models to test our vaccines in and by developing completely new vaccines. If we can test our vaccines in clinical phase I, II and III studies, this can show whether these can improve the treatment of these viral infections and thus reduce the risk that they lead to liver cancer.
- Genetic Vaccines and Immune-Based Therapies to Prevent Cancer Caused by Chronic Hepatitis B Virus and Hepatitis D Virus Infections: New Therapies and ModelsSwedish Cancer Society1 January 2018Chronic infections caused by hepatitis B virus (HBV) and hepatitis D virus (HDV) are a leading cause of liver cancer. For chronic HBV, there is currently a lifelong treatment that suppresses the viral proliferation but does not penalize the infection. For HDV, there is only 24 months of interferon treatment which only cures about 25%. Thus, there is a great need for new treatments for HBV and HDV. We intend to develop new immunological treatments for these infections. We are working on developing a treating vaccine against chronic HBV and HDV infection. This is supposed to be an addition to today's treatment. We start with a combination vaccine against HBV and HDV as a treatment for chronic HBV infection. In the studies that have begun, we have been able to show that the vaccine activates a T cell response to HBV and HDV as well as antibodies that prevent HBV / HDV from infecting new cells, so-called neutralizing antibodies. We intend to identify the best of 10 different vaccine candidates that are then developed for clinical trials in humans. In parallel with this, we also develop more experimental treatment principles. We hope that our research will lead to the treatment of chronic HBV and HDV infections being improved so that we can reduce the risk of developing cancer and serious liver damage. We believe that the vaccine we develop can give the infected control over the infection by reducing the number of cells that are infected and knocking out the cells already infected. If we succeed, this can lead to reduced suffering and reduced healthcare costs.
- Genetic Vaccines and Immune-Based Therapies to Prevent Cancer Caused by Chronic Hepatitis B Virus and Hepatitis D Virus Infections: New Therapies and ModelsSwedish Cancer Society1 January 2017Chronic infections caused by hepatitis B virus (HBV) and hepatitis D virus (HDV) are a leading cause of liver cancer. For chronic HBV, there is currently a lifelong treatment that suppresses the viral proliferation but does not penalize the infection. For HDV, there is only 24 months of interferon treatment which only cures about 25%. Thus, there is a great need for new treatments for HBV and HDV. We intend to develop new immunological treatments for these infections. We are working on developing a treating vaccine against chronic HBV and HDV infection. This is supposed to be an addition to today's treatment. We start with a combination vaccine against HBV and HDV as a treatment for chronic HBV infection. In the studies that have begun, we have been able to show that the vaccine activates a T cell response to HBV and HDV as well as antibodies that prevent HBV / HDV from infecting new cells, so-called neutralizing antibodies. We intend to identify the best of 10 different vaccine candidates that are then developed for clinical trials in humans. In parallel with this, we also develop more experimental treatment principles. We hope that our research will lead to the treatment of chronic HBV and HDV infections being improved so that we can reduce the risk of developing cancer and serious liver damage. We believe that the vaccine we develop can give the infected control over the infection by reducing the number of cells that are infected and knocking out the cells already infected. If we succeed, this can lead to reduced suffering and reduced healthcare costs.
- Vaccine and immunotherapies to prevent liver cancer caused by hepatitis B and D virusSwedish Cancer Society1 January 2015Co-infections in the liver caused by hepatitis B and D virus (HBV / HDV) often have a serious course. HDV can only multiply in liver cells that are already infected with HBV. HBV today requires lifelong treatment, but against HDV there is no good treatment. Thus, there is a great need to develop new treatments for HBV and HDV. This project focuses on developing new treatments for HBV and HDV. We have previously developed this type of treatment for hepatitis C and therefore believe that we have very good conditions for doing this also against HBV and HDV. We will produce so-called genetic vaccines, and gene therapy, to produce T cells that selectively recognize and kill liver cells infected with HBV or HDV. This makes HBV infected that they can hopefully end their lifelong treatment with antivirals as the body's own immune system controls viruses. For HDV, we hope that the infection will heal completely, or prevent it from occurring. To be able to do this in a safe and good way, attempts must be made in mouse models. We will develop a new mouse model that is more similar to human as the mouse will have human liver cells. We hope, of course, that we will be able to develop effective treatments for HBV and HDV to reduce, or even eliminate, the risk of liver cancer caused by these viruses. There are studies showing that both HBV and HDV can be controlled with a good T cell response. Thus, our goal is to be able to treat patients with chronic HBV and / or HDV in a rather near future with antigen activation of T cells with vaccine, or redirection of T cells via gene therapy. Our treating vaccine against HBV is today close to clinic testing. We think we can soon be in the same position for HDV.
- Swedish Research Council1 January 2012 - 31 December 2016
- VINNOVA8 November 2010 - 7 November 2013
- Swedish Research Council1 January 2009 - 31 December 2011
- Deutsche Forschungsgemeinschaft1 January 2006 - 31 December 2015
Employments
- Professor/Biomedical Analyst, Department of Laboratory Medicine, Karolinska Institutet, 2000-
Leadership and responsibility assignments
- Dean, KI Syd, Karolinska Institutet, 2024-